Insider · CIK 0002041874
Phillip Terry Meikle II
Files at BBLG (Bone Biologics Corp). First filing -, latest -.
In brief
Phillip Terry Meikle II files SEC Form 4 as director at BBLG (Bone Biologics Corp). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Phillip Terry Meikle II has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | BBLG Bone Biologics Corp | AGrant or award Non-Employee Stock Optionderivative | +113,896 | $0.00 | $0 | 113,896 | 13 d ago |
| Jun 4, 2025 | BBLG Bone Biologics Corp | AGrant or award Non-Employee Stock Optionderivative | +62,894 | $0.00 | $0 | 62,894 | Jun 6, 2025 |
| Oct 16, 2024 | BBLG Bone Biologics Corp | AGrant or award Non-Employee Stock Optionderivative | +9 | $0.00 | $0 | 9 | Oct 18, 2024 |
| Oct 16, 2024 | BBLG Bone Biologics Corp | AGrant or award Non-Employee Stock Optionderivative | +28,185 | $0.00 | $0 | 28,185 | Oct 18, 2024 |
Questions about Phillip Terry Meikle II
Answered from the filings on this page, as of the latest one.
Is Phillip Terry Meikle II buying or selling?
Phillip Terry Meikle II has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Phillip Terry Meikle II's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Phillip Terry Meikle II has 0.
Where does Phillip Terry Meikle II file Form 4?
Phillip Terry Meikle II has filed Form 4 at BBLG (Bone Biologics Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.